{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Intermediate-Risk+Therapy&page=2",
    "query": {
      "intervention": "Intermediate-Risk Therapy",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Intermediate-Risk+Therapy&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-06T19:40:53.675Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02920008",
      "title": "Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "guadecitabine",
          "type": "DRUG"
        },
        {
          "name": "Treatment Choice (TC)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astex Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 302,
      "start_date": "2017-03-16",
      "completion_date": "2020-06-01",
      "has_results": true,
      "last_update_posted_date": "2024-08-28",
      "last_synced_at": "2026-09-06T19:40:53.675Z",
      "location_count": 15,
      "location_summary": "Los Angeles, California • Chicago, Illinois • Indianapolis, Indiana + 11 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        },
        {
          "city": "Albuquerque",
          "state": "New Mexico"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02920008"
    },
    {
      "nct_id": "NCT00053352",
      "title": "Surgery and Combination Chemotherapy in Treating Children With Extracranial Germ Cell Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Childhood Embryonal Tumor",
        "Childhood Extracranial Germ Cell Tumor",
        "Childhood Extragonadal Germ Cell Tumor",
        "Childhood Malignant Ovarian Germ Cell Tumor",
        "Childhood Malignant Testicular Germ Cell Tumor",
        "Childhood Teratoma",
        "Ovarian Embryonal Carcinoma",
        "Ovarian Yolk Sac Tumor",
        "Stage II Malignant Testicular Germ Cell Tumor",
        "Stage IIA Ovarian Germ Cell Tumor",
        "Stage IIB Ovarian Germ Cell Tumor",
        "Stage IIC Ovarian Germ Cell Tumor",
        "Stage III Malignant Testicular Germ Cell Tumor",
        "Stage IIIA Ovarian Germ Cell Tumor",
        "Stage IIIB Ovarian Germ Cell Tumor",
        "Stage IIIC Ovarian Germ Cell Tumor",
        "Testicular Choriocarcinoma and Yolk Sac Tumor",
        "Testicular Embryonal Carcinoma"
      ],
      "interventions": [
        {
          "name": "conventional surgery",
          "type": "PROCEDURE"
        },
        {
          "name": "cisplatin",
          "type": "DRUG"
        },
        {
          "name": "etoposide",
          "type": "DRUG"
        },
        {
          "name": "bleomycin sulfate",
          "type": "BIOLOGICAL"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Children's Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": 302,
      "start_date": "2003-11-03",
      "completion_date": "2021-06-30",
      "has_results": true,
      "last_update_posted_date": "2021-07-13",
      "last_synced_at": "2026-09-06T19:40:53.675Z",
      "location_count": 112,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 98 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Downey",
          "state": "California"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00053352"
    },
    {
      "nct_id": "NCT03238027",
      "title": "A Phase 1 Study to Investigate Axatilimab Alone or in Combination With Durvalumab in Patients With Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumor",
        "Metastatic Tumor",
        "Locally Advanced Malignant Neoplasm",
        "Unresectable Malignant Neoplasm"
      ],
      "interventions": [
        {
          "name": "Axatilimab",
          "type": "DRUG"
        },
        {
          "name": "Durvalumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Syndax Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 45,
      "start_date": "2017-09-01",
      "completion_date": "2020-11-20",
      "has_results": false,
      "last_update_posted_date": "2024-05-17",
      "last_synced_at": "2026-09-06T19:40:53.675Z",
      "location_count": 5,
      "location_summary": "Scottsdale, Arizona • Baltimore, Maryland • Portland, Oregon + 1 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03238027"
    },
    {
      "nct_id": "NCT00103896",
      "title": "Connect to Protect Partnerships for Youth Prevention Interventions: Phase II",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "HIV Infection"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of North Carolina, Chapel Hill",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "24 Years",
        "sex": "ALL",
        "summary": "12 Years to 24 Years"
      },
      "enrollment_count": 16706,
      "start_date": "2003-09",
      "completion_date": "2010-10",
      "has_results": false,
      "last_update_posted_date": "2017-03-01",
      "last_synced_at": "2026-09-06T19:40:53.675Z",
      "location_count": 14,
      "location_summary": "Los Angeles, California • San Diego, California • San Francisco, California + 11 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00103896"
    },
    {
      "nct_id": "NCT04411602",
      "title": "Intermediate IND Severe Illness COVID-19 CP",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Severe Acute Respiratory Syndrome",
        "COVID"
      ],
      "interventions": [
        {
          "name": "SARS-CoV-2 plasma",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Henry Ford Health System",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2020-04-07",
      "completion_date": "2021-04-07",
      "has_results": false,
      "last_update_posted_date": "2025-12-19",
      "last_synced_at": "2026-09-06T19:40:53.675Z",
      "location_count": 3,
      "location_summary": "Novi, Michigan • Southfield, Michigan • Warren, Michigan",
      "locations": [
        {
          "city": "Novi",
          "state": "Michigan"
        },
        {
          "city": "Southfield",
          "state": "Michigan"
        },
        {
          "city": "Warren",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04411602"
    },
    {
      "nct_id": "NCT04390737",
      "title": "Evaluate the Safety and Clinical Activity of HH2853",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "FL Lymphoma",
        "Epithelioid Sarcoma",
        "Peripheral T Cell Lymphoma",
        "Advanced Solid Tumor"
      ],
      "interventions": [
        {
          "name": "HH2853 Tablets",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Haihe Biopharma Co., Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 254,
      "start_date": "2020-09-08",
      "completion_date": "2028-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-01-30",
      "last_synced_at": "2026-09-06T19:40:53.675Z",
      "location_count": 4,
      "location_summary": "Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota + 1 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04390737"
    },
    {
      "nct_id": "NCT02946879",
      "title": "Long-Term Follow-Up Gene Therapy Study for Leber Congenital Amaurosis OPTIRPE65 (Retinal Dystrophy Associated With Defects in RPE65)",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Leber Congenital Amaurosis (LCA)",
        "Eye Diseases",
        "Eye Diseases, Hereditary",
        "Retinal Diseases"
      ],
      "interventions": [
        {
          "name": "AAV OPTIRPE65",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "MeiraGTx UK II Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "3 Years to 100 Years"
      },
      "enrollment_count": 15,
      "start_date": "2016-11",
      "completion_date": "2023-07",
      "has_results": false,
      "last_update_posted_date": "2024-04-11",
      "last_synced_at": "2026-09-06T19:40:53.675Z",
      "location_count": 1,
      "location_summary": "Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02946879"
    },
    {
      "nct_id": "NCT04995029",
      "title": "Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in High-risk Users",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Moderate to Severe Opioid-use Disorder"
      ],
      "interventions": [
        {
          "name": "Transmucosal Buprenorphine",
          "type": "DRUG"
        },
        {
          "name": "Extended-release Buprenorphine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Indivior Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 785,
      "start_date": "2021-10-26",
      "completion_date": "2024-06-26",
      "has_results": true,
      "last_update_posted_date": "2026-02-06",
      "last_synced_at": "2026-09-06T19:40:53.675Z",
      "location_count": 28,
      "location_summary": "Garden Grove, California • Panorama City, California • San Diego, California + 21 more",
      "locations": [
        {
          "city": "Garden Grove",
          "state": "California"
        },
        {
          "city": "Panorama City",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Bay Pines",
          "state": "Florida"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04995029"
    },
    {
      "nct_id": "NCT03001310",
      "title": "Gene Therapy for Achromatopsia (CNGB3)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Achromatopsia"
      ],
      "interventions": [
        {
          "name": "AAV - CNGB3",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "MeiraGTx UK II Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "3 Years and older"
      },
      "enrollment_count": 23,
      "start_date": "2017-01-16",
      "completion_date": "2019-10-25",
      "has_results": true,
      "last_update_posted_date": "2023-03-08",
      "last_synced_at": "2026-09-06T19:40:53.675Z",
      "location_count": 1,
      "location_summary": "Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03001310"
    },
    {
      "nct_id": "NCT04818242",
      "title": "Dexcom Continuous Glucose Monitoring in Long-term Care",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Diabetes",
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "Dexcom G6 CGM with GTS",
          "type": "DEVICE"
        },
        {
          "name": "POC Blood Glucose Test + Blinded CGM",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2021-04-19",
      "completion_date": "2022-10-21",
      "has_results": true,
      "last_update_posted_date": "2023-11-13",
      "last_synced_at": "2026-09-06T19:40:53.675Z",
      "location_count": 2,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04818242"
    }
  ]
}